Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea.

ABSTRACT:

Background

Real-world clinical data concerning regdanvimab, a monoclonal antibody treatment for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), are urgently needed. Here, we describe our experience with regdanvimab.

Materials and methods

This retrospective cohort study enrolled high-risk adults with mild-to-moderate COVID-19 who were admitted to a dedicated COVID-19 hospital in Korea from March to September 2021. We used multiple logistic regression and propensity score-matching to compare the outcomes of patients who did or did not receive regdanvimab. The primary outcome was in-hospital progression to severe or critical status, or death.

Results

Of 586 patients eligible for regdanvimab, 256 patients who received regdanvimab and 251 untreated pati

SUBMITTER: Hong SI 

PROVIDER: S-EPMC8987179 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature